RayKnowChina Research Map
Shortlist0

RecruitingMoyamoya diseasePhase not stated

Registered title, quoted from ClinicalTrials.gov

Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

An open trial on moyamoya disease, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06817434, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 60 years; sex: all

    Registered eligibility fields

  2. Pregnant patients;

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06817434, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The imaging examination meets the diagnostic criteria for moyamoya disease;
  • Sign the informed consent form;
  • Age ≥18 years old;
  • Baseline mRS score ≤2 points;
  • The patient receives revascularization/conservative treatment;
  • There is at least 1 imaging follow-up result.

Exclusion Criteria:

  • Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;
  • Individuals under the age of 18;
  • Participants who refuse to take part in this study;
  • Pregnant patients;
  • Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;
  • A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;
  • Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;
  • Allergies to contrast media;
  • Patients with missing imaging data or whose image quality cannot be analyzed;
  • Individuals who refuse or are unable to undergo imaging follow-up;
  • Patients receiving other types of lipid-lowering drug treatments.

Quoted from ClinicalTrials.gov, NCT06817434, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06817434, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06817434